Healthcare Triangle, Inc. HCTI
0.78
0.05
6.85%
as of 25 Sep
- Market cap
- $10.5M
- P/E
- 0.0×
Follow HCTI
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
0.20 | 0.13 | 0.17 | 0.90 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(6.10) | (0.36) | (0.34) | (7.82) | |
P/B ratio |
0.21 | 0.09 | 0.94 | 9.07 | |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Sales |
0.58 | 0.39 | 0.46 | 0.97 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(0.94) | (0.44) | (0.38) | (1.19) | |
EV/FCF |
(0.85) | (0.41) | (0.35) | (1.06) | |
Quick Ratio |
0.51 | 0.60 | 0.76 | 1.04 | |
Current Ratio |
0.60 | 0.90 | 1.03 | 2.03 | |
Net Debt/EBITDA |
(2.80) | (1.92) | (0.82) | 0.04 | |
Debt/Assets |
16.06% | 12.12% | 47.22% | 11.06% | |
Debt/Equity |
0.24 | 0.18 | 1.08 | 0.18 | |
Asset Turnover |
0.58 | 0.44 | 1.12 | 1.39 | |
Operating CF/Net income |
0.19 | 1.11 | 1.52 | 0.79 | |
Capex/Depreciation |
(0.05) | (0.03) | (0.34) | (20.41) | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.55% | 0.86% | 8.85% | 1.69% | |
Selling, General and Administrative Expense of Revenue |
60.27% | 50.70% | 125.64% | 89.05% | |
Intangible Assets out of Total Assets |
0.78 | 0.73 | 0.25 | 0.43 | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 11.89% | |
Graham Net Nets |
(2.93) | (3.42) | 0.15 | 0.24 | |
Graham Number |
682.34 | 1,262.84 | 0.00 | 0.00 | |
Earnings Yield |
135,562.21% | 89,981.60% | (309.62%) | (3,832.64%) | |
Free Cash Flow Yield |
(346.06%) | (772.88%) | (767.01%) | (100.77%) | |
Revenue per Share |
3.28 | 10.59 | 50.73 | 47.02 | |
Operating CF per Share |
(0.30) | (7.37) | (110.40) | (20.18) | |
Capex per Share |
(0.01) | (0.02) | (3.47) | (17.33) | |
Free Cash Flow per Share |
(0.31) | (7.40) | (113.88) | (37.51) | |
Cash per Share |
0.68 | 4.63 | 123.18 | 21.95 | |
Shareholders Equity per Share |
17.50 | 56.60 | 160.65 | 117.60 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
17.50 | 56.60 | 160.65 | 117.60 | |
Free Cash Flow |
(0.86) | (6.89) | (7.05) | (2.78) | |
Working Capital |
(6.34) | (2.10) | 0.36 | 4.03 | |
Capital Expenditures |
(0.02) | (0.02) | (0.21) | (1.29) | |
Net Current Asset Value |
(14.89) | (8.57) | 0.36 | 2.83 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.00 | 0.07 | 0.37 | |
Net Profit Margin |
(48.03%) | (62.89%) | (143.41%) | (54.63%) | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
4.02 | 5.14 | 1.59 | 2.03 | |
Average Payables |
1.64 | 2.45 | 1.64 | 1.80 | |
Average Assets |
44.10 | 45.97 | 12.35 | 9.30 | |
Average Common Equity |
13.22 | 14.20 | (5.02) | (0.26) |
Columns are period end dates